MX357402B - Metodo para predecir el pronostico de cancer de mama. - Google Patents

Metodo para predecir el pronostico de cancer de mama.

Info

Publication number
MX357402B
MX357402B MX2014005547A MX2014005547A MX357402B MX 357402 B MX357402 B MX 357402B MX 2014005547 A MX2014005547 A MX 2014005547A MX 2014005547 A MX2014005547 A MX 2014005547A MX 357402 B MX357402 B MX 357402B
Authority
MX
Mexico
Prior art keywords
breast cancer
cancer prognosis
predicting breast
predicting
relates
Prior art date
Application number
MX2014005547A
Other languages
English (en)
Other versions
MX2014005547A (es
Inventor
B Baker Joffre
V Sinicropi Dominick
J Pelham Robert
Crager Michael
Collin Francois
C Stephans James
Liu Mei-Lan
Morlan John
Qu Kunbin
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2014005547A publication Critical patent/MX2014005547A/es
Publication of MX357402B publication Critical patent/MX357402B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a un método in vitro para predecir una probabilidad de supervivencia durante al menos 3 años sin recurrencia de cáncer de mama en un paciente con cáncer de mama, caracterizado porque comprende: determinar un nivel del biomarcador pronóstico del cáncer de mama del miembro de la familia de quinesina 1B (KIF1B) en una muestra de tumor de cáncer de mama del paciente, normalizar el nivel del biomarcador pronóstico del cáncer de mama KIF1B para obtener un nivel normalizado de KIF1B; y predecir una probabilidad de supervivencia durante al menos 3 años sin recurrencia de cáncer de mama del paciente, en donde un nivel normalizado aumentado del biomarcador pronóstico del cáncer de mama KIF1B en comparación con la cantidad encontrada en un conjunto de referencia de tejido canceroso se correlaciona negativamente con una probabilidad aumentada de supervivencia durante al menos 3 años sin recurrencia de cáncer de mama.
MX2014005547A 2011-11-08 2012-11-02 Metodo para predecir el pronostico de cancer de mama. MX357402B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557238P 2011-11-08 2011-11-08
US201261597426P 2012-02-10 2012-02-10
PCT/US2012/063313 WO2013070521A1 (en) 2011-11-08 2012-11-02 Method of predicting breast cancer prognosis

Publications (2)

Publication Number Publication Date
MX2014005547A MX2014005547A (es) 2014-08-29
MX357402B true MX357402B (es) 2018-07-09

Family

ID=48290467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005547A MX357402B (es) 2011-11-08 2012-11-02 Metodo para predecir el pronostico de cancer de mama.

Country Status (10)

Country Link
US (4) US20140296085A1 (es)
EP (1) EP2776830B1 (es)
JP (2) JP6147755B2 (es)
AU (1) AU2012336120B2 (es)
CA (1) CA2854805C (es)
HK (1) HK1201329A1 (es)
IL (4) IL232445B (es)
MX (1) MX357402B (es)
SG (2) SG11201402042PA (es)
WO (1) WO2013070521A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
CN103998064A (zh) 2010-12-09 2014-08-20 生物诊断治疗公司 治疗后的乳腺癌预后
CN104685071A (zh) * 2012-09-18 2015-06-03 凯杰有限公司 制备靶rna消除组合物的方法和试剂盒
WO2014110230A2 (en) * 2013-01-09 2014-07-17 Health Research, Inc. Methods for diagnosing cancer based on small nucleolar rna hbii-52
WO2014130444A1 (en) * 2013-02-19 2014-08-28 Genomic Health, Inc. Method of predicting breast cancer prognosis
US20150203921A1 (en) * 2013-09-11 2015-07-23 Biotheranostics, Inc. Predicting breast cancer recurrence
US20160259881A1 (en) * 2013-10-29 2016-09-08 Genomic Health, Inc. Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
CN105214077B (zh) * 2014-06-03 2019-02-05 浙江阿思科力生物科技有限公司 Usp33在肿瘤中的应用
WO2016094330A2 (en) * 2014-12-08 2016-06-16 20/20 Genesystems, Inc Methods and machine learning systems for predicting the liklihood or risk of having cancer
RU2017124373A (ru) * 2014-12-10 2019-01-10 Конинклейке Филипс Н.В. Способы и система для создания сетей коэкспрессии некодирующих и кодирующих генов
US10889866B2 (en) 2015-09-01 2021-01-12 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic SF3B1 mutants
EP3719143B1 (en) 2015-10-23 2023-07-26 Novartis AG Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
BR112018009528A2 (pt) 2015-11-13 2018-11-06 Biotheranostics Inc método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama
EP3202913B1 (en) * 2016-02-08 2019-01-30 King Faisal Specialist Hospital And Research Centre A set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival
EP3624897A4 (en) * 2017-05-19 2021-07-14 Lunella Biotech, Inc. COMPANION DIAGNOSIS FOR MITOCHONDRIAL INHIBITORS
EP3802816A4 (en) * 2018-06-08 2022-03-23 Glympse Bio, Inc. ACTIVITY SENSOR DESIGN
CN108893537B (zh) * 2018-07-19 2020-10-30 青岛泱深生物医药有限公司 C7orf70及其应用
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US20220002815A1 (en) * 2018-11-04 2022-01-06 Pfs Genomics, Inc. Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
WO2021216990A1 (en) * 2020-04-23 2021-10-28 Board Of Regents, The University Of Texas System Methods and compositions related to full-length excised intron rnas (flexi rnas)
RU2763839C1 (ru) * 2021-04-27 2022-01-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Петрова" Минздрава России) Способ многофакторного прогноза рака молочной железы
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
JP7253288B1 (ja) 2022-01-04 2023-04-06 株式会社タクボ精機製作所 ロータリ乾燥炉
CN114480650A (zh) * 2022-02-08 2022-05-13 深圳市陆为生物技术有限公司 一种预测三阴乳腺癌临床预后复发风险的标志物及模型
CN114657242B (zh) * 2022-03-16 2022-11-11 广州医科大学附属第一医院 Gpr33基因在马尔尼菲篮状菌易感人群评估的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529535T1 (de) * 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
DK1644858T3 (da) * 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
EP1797429A2 (en) * 2004-09-30 2007-06-20 Bayer HealthCare AG Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
US20100105564A1 (en) * 2006-09-15 2010-04-29 Mcgill University Stroma Derived Predictor of Breast Cancer
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
EP2036988A1 (en) * 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009071655A2 (en) * 2007-12-06 2009-06-11 Siemens Healthcare Diagnostics Inc. Methods for breast cancer prognosis
US20110020370A1 (en) * 2008-12-11 2011-01-27 Elias Georges Slc7a5 directed diagnostics and therapeutics for neoplastic disease
CN101851611A (zh) * 2009-04-01 2010-10-06 天津医科大学附属肿瘤医院 驱动蛋白样蛋白kif1b的转移相关功能和预测肿瘤患者预后的标志物用途及其应用方法
WO2010127399A1 (en) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2011044513A1 (en) * 2009-10-08 2011-04-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
EP2504451B1 (en) * 2009-11-23 2019-06-05 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP2507397A4 (en) * 2009-12-01 2013-05-01 Compendia Bioscience Inc CLASSIFICATION OF CANCERS
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
US20130143753A1 (en) * 2010-03-01 2013-06-06 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
CA2793133C (en) * 2010-03-31 2019-08-20 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment

Also Published As

Publication number Publication date
SG11201402042PA (en) 2014-06-27
IL276488B (en) 2021-04-29
EP2776830B1 (en) 2018-05-09
IL261708A (en) 2018-10-31
US20190256923A1 (en) 2019-08-22
EP2776830A1 (en) 2014-09-17
SG10202010758SA (en) 2020-11-27
IL265136B (en) 2020-08-31
EP2776830A4 (en) 2015-07-15
NZ624700A (en) 2016-08-26
JP6147755B2 (ja) 2017-06-14
CA2854805C (en) 2021-04-27
US20160222463A1 (en) 2016-08-04
IL232445B (en) 2018-10-31
MX2014005547A (es) 2014-08-29
HK1201329A1 (en) 2015-08-28
JP2017055769A (ja) 2017-03-23
IL232445A0 (en) 2014-06-30
CA2854805A1 (en) 2013-05-16
IL276488A (en) 2020-09-30
AU2012336120A1 (en) 2014-05-29
AU2012336120B2 (en) 2017-10-26
WO2013070521A1 (en) 2013-05-16
JP2014532428A (ja) 2014-12-08
US20140296085A1 (en) 2014-10-02
US20200263257A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX340453B (es) Biomarcadores para cancer de pulmon.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
HK1187377A1 (zh) 用於對乳腺癌的轉移進行診斷、預後和治療的方法
WO2013006495A3 (en) Methods of predicting prognosis in cancer
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
HK1181817A1 (en) Method for breast cancer recurrence prediction under endocrine treatment
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
HK1204481A1 (en) Method for in vitro diagnosis or prognosis of colon cancer
WO2014072832A3 (en) Biomarkers for cervical cancer
WO2013173500A3 (en) Method for predicting recurrence of melanoma using mirna alterations
UA75385U (ru) Способ прогнозирования развития рака молочной железы у женщин с отягощенной наследственностью
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
RU2011107075A (ru) Способ прогнозирования уровня пролиферации рака молочной железы
UA56092U (ru) Способ определения твердости асфальтобетонных покрытий
UA55887U (ru) Способ диагностики риска прогрессии гиперплазии эндометрия в передрак и рак эндометрия

Legal Events

Date Code Title Description
FG Grant or registration